enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Merck's Keytruda gets FDA nod for expanded use in lung cancer

   www.aol.com/news/mercks-keytruda-gets-u-fdas...

   The U.S. health regulator's approval extends Keytruda's use in combination with chemotherapy as a treatment given before surgery to shrink the size of the tumor in patients. The U.S. drugmaker is ...

3. Merck stops testing combo drug for lung cancer - AOL

   www.aol.com/news/merck-stops-testing-combo-drug...

   (Reuters) -Merck said on Thursday it had discontinued a trial testing a combination immunotherapy treatment in patients with a type of lung cancer after an interim analysis showed the drug was ...

4. Merck's lung cancer drug combo fails trial in setback for new ...

   www.aol.com/news/mercks-lung-cancer-drug-combo...

   Merck's experimental anti-TIGIT drug vibostolimab in combination with its approved therapy Keytruda also failed to improve overall survival in a study of patients with non-small-cell lung cancer ...

5. Merck's Keytruda sets new 5-year survival standard for ... - AOL

   www.aol.com/news/mercks-keytruda-sets-5-survival...

   Nearly a quarter of patients who received Merck & Co's immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according to data presented at a ...

6. Pembrolizumab - Wikipedia

   en.wikipedia.org/wiki/Pembrolizumab

   Micrograph showing a PD-L1 positive non-small cell lung carcinoma. PD-L1 immunostain. As of 2019, pembrolizumab is used via intravenous infusion to treat inoperable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC) in certain situations, as a first-line treatment for metastatic bladder cancer in patients who cannot receive cisplatin-based chemotherapy and have high levels ...

7. Merck scraps two late-stage trials of cancer drug Keytruda

   www.aol.com/news/merck-scraps-two-stage-trials...

   A trial of the drug in patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma was stopped for "futility", meaning it was likely to fail, the company said.

8. Merck's Keytruda Improves 5-Year Survival in Lung Cancer - AOL

   www.aol.com/news/mercks-keytruda-improves-5...

   Merck (MRK) presents longest follow-up data for Keytruda in advance lung cancer at ASCO 2019. The five-year overall survival rates in the Keytruda arm are better than historical rates

9. Merck, Novocure Team Up On Lung Cancer Treatment; Trial ... - AOL

   www.aol.com/news/merck-novocure-team-lung-cancer...

   Merck (MRK) and Novocure (NVCR) have entered into a clinical trial collaboration agreement to develop Tumor Treating Fields together with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) for ...